Migren Ataklarının Akut Tedavisi
Özet
Migren, dünya genelinde yaygın olarak görülen ve önemli bir özürlülük nedeni olan, tedavisi kişiye özel planlanması gereken karmaşık bir hastalıktır. İdeal bir migren tedavisinin atağı en kısa sürede, ağrıyı tamamen sonlandıracak ve yan etki oluşturmayacak şekilde sonlandırması istense de, her hastayı kapsayacak tek bir model bulunmamaktadır. Akut migren tedavisinde farmakolojik yöntemler arasında ilk basamak olarak hafif ve orta ağrılarda asetaminofen ve NSAİİ'lar tercih edilirken; orta ve ağır ataklarda migrene spesifik triptanlar, ergot alkaloidleri, dopamin reseptör antagonisti olan antiemetikler, kortikosteroidler ve son yıllarda onay alan gepantlar ile ditanlar gibi yeni ilaç grupları kullanılmaktadır. Farmakolojik ajanların yanı sıra, ilaç yan etkilerine hassas veya dirençli hastalarda eksternal trigeminal nörostimülasyon, tek vuru transkraniyal stimülasyon ve non-invaziv vagal sinir stimülasyonu gibi non-farmakolojik tedavi yöntemleri de tek başına veya tedaviye ek olarak denenebilmektedir. Tedavi stratejileri belirlenirken ağrının şiddeti, ilerleme hızı, ağrı tekrarı, bulantı/kusma varlığı ve hastanın gebelik veya emzirme durumu gibi özel koşulları dikkate alınarak kişiselleştirilmiş yaklaşımlar (gruba dayalı veya aşamalı tedavi) uygulanmalıdır.
Migraine is a complex disease that is widespread globally, serves as a major cause of disability, and requires a personalized treatment plan. Although an ideal migraine treatment is expected to terminate the attack as quickly as possible, completely end the pain, and cause no side effects, there is no single model that fits every patient. Among pharmacological methods in acute migraine treatment, acetaminophen and NSAIDs are preferred as the first step for mild to moderate pain, whereas migraine-specific triptans, ergot alkaloids, antiemetics acting as dopamine receptor antagonists, corticosteroids, and recently approved new drug classes such as gepants and ditans are utilized for moderate to severe attacks. In addition to pharmacological agents, non-pharmacological treatment methods like external trigeminal neurostimulation, single-pulse transcranial stimulation, and non-invasive vagus nerve stimulation can be attempted alone or adjunctively in patients who are sensitive to drug side effects or refractory to treatment. When determining treatment strategies, personalized approaches (stratified or step-care therapy) must be applied by considering specific conditions such as the severity of pain, speed of progression, headache recurrence, presence of nausea/vomiting, and the patient's pregnancy or lactation status.
Referanslar
Rose FC. The history of the migraine trust. J Headache Pain. 2006;7(2):109–15.
Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci [Internet]. 2017;372:307–15. Available from: http://dx.doi.org/10.1016/j.jns.2016.11.071
Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain [Internet]. 2016;17(1):0–3. Available from: http://dx.doi.org/10.1186/s10194-016-0699-5
Road C. The International Classification of Headache Disorders , 3rd edition ( beta version ). 2013;33(9):629–808.
Tepper SJ. Acute Treatment of Migraine. Vol. 37, Neurologic Clinics. W.B. Saunders; 2019. p. 727–42.
Ong JJY, De Felice M. Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action. Vol. 15, Neurotherapeutics. Springer Science and Business Media Deutschland GmbH; 2018. p. 274–90.
Becker WJ. Acute Migraine Treatment. :953–72.
Derry S, Ra M. Paracetamol ( acetaminophen ) with or without an antiemetic for acute migraine headaches in adults ( Review ). 2013;(6).
Rabbie R, Derry S, Ra M. Ibuprofen with or without an antiemetic for acute migraine headaches in adults ( Review ). 2013;(4).
Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: Systematic review and meta-analysis. Ann Pharmacother. 2007;41(11):1782–91.
Becker WJ. Acute Migraine Treatment in Adults. 2015;778–93.
Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino J V, Quiring JN, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine : Results from the International Migraine Pain Assessment Clinical Trial ( IMPACT ). 2010;30(11):1336–45.
Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. Meta-Analysis of the Efficacy and Safety of Naproxen Sodium. 2010;808–18.
Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid , paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache : a multicentre , group study. 2005;(2):776–87.
Study P, Goldstein J, Silberstein SD, Saper JR, Ryan RE, Lipton RB. Acetaminophen , Aspirin , and Caffeine in Combination Versus Ibuprofen for Acute Migraine : Results From a. 2006;444–53.
Vanderpluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. Vol. 325, JAMA - Journal of the American Medical Association. American Medical Association; 2021. p. 2357–69.
Diener HC, Montagna P, Gács G, Lyczak P, Schumann G, Zöller B, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26(5):537–47.
Brandes JLJ, Kudrow D, Stark SR, Carroll CPO, Adelman JU, Donnell FJO, et al. Sumatriptan-naproxen for acute treatment of migraine. JAMA J … [Internet]. 2007;297(13):1443–54. Available from: http://jama.ama-assn.org/content/297/13/1443.short%5Cnhttp://jama.ama-assn.org/content/297/13/1443.abstract
Villalón* CM, VanDenBrink AM. 5-HT -Iike receptor agonists and the pathophysiologyof migraine. Mini-Reviews Med Chem [Internet]. 2017;17(11):928–38. Available from: https://0-ac-els--cdn-com.pugwash.lib.warwick.ac.uk/0165614789902381/1-s2.0-0165614789902381-main.pdf?_tid=736e0a7a-e4f8-11e7-9f1f-00000aab0f6c&acdnat=1513714320_32e1ef77415c072a9a6503c18faec54b
Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005;115(1–2):1–4.
Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - A review. Cephalalgia. 2004;24(5):321–32.
Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME. Which triptan for which patient? Neurol Sci. 2006;27(SUPPL. 2):123–9.
Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia. 2014;34(4):258–67.
Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The Triptan Formulations. CNS Drugs. 2003;17(6):431–47.
Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, VanDenBrink AM, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–25.
Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): A review: Review article. Headache. 2010;50(2):264–72.
Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American headache society position paper. Headache. 2010;50(6):1089–99.
Tullo V, Valguarnera F, Barbanti P, Cortelli P, Sette G, Allais G, et al. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: A randomized study. Cephalalgia. 2014;34(6):434–45.
Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons. Headache. 2010;50(9):1424–39.
Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–32.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan 1;55(1):3–20.
Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TempoTM) inhaler. Headache. 2008;48(3):355–67.
Mayans L, Willing A. Acute Migraine Headache: Treatment Strategies. Am Fam Physician. 2018;15;97(4):243-251.
Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Láinez M, Henry P, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain. 2000;123(1):9–18.
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55(S4):221–35.
Silberstein SD, Freitag FG, Rozen TD, Kudrow DB, Hewitt DJ, Jordan DM, et al. Tramadol/acetaminophen for the treatment of acute migraine pain: Findings of a randomized, placebo-controlled trial. Headache. 2005;45(10):1317–27.
Silberstein SD, Edlund W. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–62.
Derosier F, Sheftell F, Silberstein S, Cady R, Ruoff G, Krishen A, et al. Sumatriptan-naproxen and butalbital: A double-blind, placebo-controlled crossover study. Headache. 2012;52(4):530–43.
Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009;49(3):395–403.
Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci. 2013;34(SUPPL. 1):235–8.
Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: Meta-analysis of randomised controlled trials. Br Med J. 2004;329(7479):1369–72.
MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13(2):124–7.
Donaldson D, Sundermann R, Jackson R, Bastani A. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med. 2008;26(2):124–30.
Rowe BH, Colman I, Edmonds ML, Blitz S, Walker A, Wiens S. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache. 2008;48(3):333–40.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 3: Opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012;52(3):467–82.
Friedman BW, Greenwald P, Bania TC, Esses D, Hochberg M, Solorzano C, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69(22):2038–44.
Scott LJ. Rimegepant: First Approval. Drugs [Internet]. 2020;80(7):741–6. Available from: https://doi.org/10.1007/s40265-020-01301-3
Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs [Internet]. 2019;28(6):555–67. Available from: https://doi.org/10.1080/13543784.2019.1618830
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The achieve ii randomized clinical trial. JAMA - J Am Med Assoc. 2019;322(19):1887–98.
Lamb YN. Lasmiditan: First Approval. Drugs [Internet]. 2019;79(18):1989–96. Available from: https://doi.org/10.1007/s40265-019-01225-7
Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action-review of a selective 5-HT 1F agonist The Journal of Headache and Pain. 2020;3:1–13. Available from: http://creativecommons.org/licenses/by/4.0/.TheCreativeCommonsPublicDomainDedicationwaiver%0Ahttp://creativecommons.org/publicdomain/zero/1.0/
Macone AE, Perloff MD. Lasmiditan: Its Development and Potential Use. Clin Pharmacol Drug Dev. 2020;9(3):292–6.
Doty EG, Krege JH, Pohl G, Case M, Dowsett SA, Tepper SJ. Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant. Headache. 2020;60(8):1793–6.
Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs—Lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Vol. 12, Pharmaceutics. MDPI AG; 2020. p. 1–22.
Tassorelli C, Grazzi L, De Tommaso M, Pierangeli G, Martelletti P, Rainero I, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology. 2018;91(4):e364–73.
Diener HC, Bussone G, De Liano H, Eikermann A, Englert R, Floeter T, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24(11):947–54.
Lipton RB, Stewart WF, Stone AM, Láinez MJA, Sawyer JPC. Stratified Care vs Step Care Strategies for Migraine. Jama. 2000;284(20):2599.
Ahrens SP, Farmer M V., Williams DL, Willoughby E, Jiang K, Block GA, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia. 1999;19(5):525–30.
Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: A double-blind, randomised, three-attack study. Eur Neurol. 2002;47(2):88–98.
Doggrell SA, Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. 2014;13(1):131–8.
Khan RB. Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol. 2002;17(11):857–8.
Jones EB, Gonzalez ER, Boggs JG, Grillo JA, Elswick RK. Safety and Efficacy of Rectal Prochlorperazine for the Treatment of Migraine in the Emergency Department. Ann Emerg Med. 1994;24(2):237–41.
Ferrari MD, James MH, Pilgrim A, Ashford E, Bates D, Anderson BA, et al. Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14(5):330–8.
Géraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376–88.
Tepper SJ, Donnan GA, Dowson AJ, Bomhof MAM, Elkind A, Meloche J, et al. A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin. 1999;15(4):254–71.
Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11(10):671–7.
Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: Results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67(12):1253–61.
Daniel S, Koren G, Lunenfeld E, Bilenko N, Ratzon R, Levy A. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. Cmaj. 2014;186(5):177–82.
Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: Results from the Norwegian mother and child cohort study. Headache. 2010;50(4):563–75.
Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(5):S1–80.
Ward RM, Bates BA, Benitz WE, Burchfield DJ, Ring JC, Walls RP, et al. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776–89.
Hendrickson RG, McKeown NJ. Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol. 2012;50(1):1–14.
